Cargando…
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma
Mantle cell lymphoma (MCL) is considered incurable with the available chemoimmunotherapy approaches, and therefore, newer effective targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly. We aimed to d...
Autores principales: | Narkhede, Mayur, Goyal, Gaurav, Shea, Lauren, Mehta, Amit, Giri, Smith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327535/ https://www.ncbi.nlm.nih.gov/pubmed/35561314 http://dx.doi.org/10.1182/bloodadvances.2022007247 |
Ejemplares similares
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023) -
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022) -
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022) -
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
por: Nikkarinen, Anna, et al.
Publicado: (2023) -
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)